Zytokinblockade zur Behandlung rheumatologischer Erkrankungen

Zusammenfassung

Die Interleukine IL-1 und IL-6 sind von elementarer pathogenetischer Bedeutung bei der Entstehung der rheumatoiden Arthritis und damit Angriffspunkte für die Entwicklung neuer Behandlungsstrategien. Die Interleukin-Rezeptor-Antagonisten Anakinra und Tocilizumab dienen neben bzw. bei Versagen der anderen Biologika als Therapieoption mit dem Ziel einer anhaltenden Remission und Verhinderung einer Gelenkdestruktion. Aktu-ell wird in Studien der Einsatz auch bei weiteren entzündlich-rheumatologischen Erkrankungen erprobt. Nach präziser Indikationsstellung, Ausschluss von Kontraindikationen und bei korrekter Therapieüberwachung kann die rheumatoide Arthritis mit Hilfe von Anakinra oder Tocilizumab erfolgreich behandelt werden.

Summary

Interleukin-1 and Interleukin-6 play an important role in the pathogenesis of rheumatoid arthritis and can therefore serve as targets for new therapies. Following unsuccessful attempts of application of other biologicals or administered concomitantly to methotrexate or other conventional DMARD, the interleukin-receptor antagonists anakinra and tocilizumab offer an alternative therapy to prevent joint destruction and to achieve continuous remission. Recent studies investigate their potential and efficacy in a number of inflammatory diseases. Both medications can be very successful in ameliorating signs and symptoms of rheumatic diseases with tocilizumab offering greater potential in rheumatoid arthritis.

Schlüsselwörter

Rheumatoide Arthritis - Anakinra - Tocilizumab - Interleukin-Rezeptor-Antagonist

Keywords

Rheumatoid arthritis - anakinra - tocilizumab - interleukin-receptor antagonist

• Literatur

• 1 Emery P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.. Ann Rheum Dis 2008; 67: 1516-1523.
• 2 Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.. Clin Ther 2004; 26: 1960-1975.
• 3 Furst DE. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. 2008; Ann Rheum Dis 2008; 67 (Suppl. 03) iii2-25.
• 4 Genovese MC. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.. Arthritis Rheum 2008; 58: 2968-2980.
• 5 Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis.. Ther Clin Risk Manag 2008; 4: 767-775.
• 6 Nishimoto N. et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.. Blood 2000; 95: 56-61.
• 7 Pierer M, Baerwald C. Biological therapy for the treatment of rheumatic diseases.. Internist (Berl) 2008; 49: 938-946.
• 8 Rose-John S. et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.. Expert Opin Ther Targets 2007; 11: 613-624.